Harpoon Therapeutics Inc., a clinical-stage immunotherapy company based in South San Francisco, is at the forefront of a groundbreaking pursuit to develop a new class of T cell engagers. Utilizing this innovative platform, the company aims to tap into the body's natural immune system to effectively treat cancer and other diseases. Harpoon's product candidate, the tri-specific T cell activating construct, or TriTAC, includes two promising drugs in the clinical trial phase. The HPN328 is currently undergoing Phase I and II trials to combat small cell lung cancer and tumors expressing Delta-like canonical Notch ligand 3, while the HPN217 is undergoing Phase I trials for multiple myeloma. Harpoon also boasts a preclinical stage product, the HPN601, designed to address multiple solid tumor indications. The company has secured a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and market products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics was established in 2015 and seeks to revolutionize immunotherapy in the United States.
Harpoon Therapeutics's ticker is HARP
The company's shares trade on the NASDAQ stock exchange
They are based in South San Francisco, California
There are 51-200 employees working at Harpoon Therapeutics
It is harpoontx.com
Harpoon Therapeutics is in the Healthcare sector
Harpoon Therapeutics is in the Biotechnology industry
The following five companies are Harpoon Therapeutics's industry peers: